[CME: Hypertriglyceridemia].

CME: Hypertriglyceridemia The European Society of Cardiology defines hypertriglyceridaemia as fasting triglycerides >1,7mmol/l. Most patients are asymptomatic. Hypertriglyceridaemia is associated with an elevated risk of cardiovascular diseases and acute pancreatitis.

Hypokalaemic metabolic alkalosis, hypertension and diabetes: what is the link.

Two years after diagnosis of a metastatic neuroendocrine gastrin-secreting tumour and after several cycles of chemotherapy and peptide receptor radionuclide therapy, a 56-year-old woman presented with hypokalaemic metabolic alkalosis, hypertension, leg oedema and new-onset diabetes mellitus. Further investigations revealed renal potassium loss confirmed by a transtubular potassium gradient of 16, fully suppressed serum aldosterone, but instead highly elevated blood levels of morning cortisol and adrenocorticotropic hormone as well as increased urinary excretion of glucocorticoid and mineralocorticoid metabolites. Ruling out other causes, paraneoplastic hypercortisolism was diagnosed.

A 10-Year Prospective Study of Bone Mineral Density and Bone Turnover in Males and Females With Type 1 Diabetes.

Context: In a previous community-based, cross-sectional study, males with type 1 diabetes (T1D) had lower bone mineral density (BMD) than did matched people without diabetes but females with T1D had normal BMD.

Objective: To determine whether BMD in the males continued to decline, the neutral effect of T1D on BMD in females persisted, and whether temporal BMD changes reflected changes in bone turnover markers.

Design: Longitudinal observational study.

A five-year prospective study of bone mineral density in men and women with diabetes: the Fremantle Diabetes Study.

To examine longitudinally the effect of diabetes on bone structure and metabolism, we measured bone mineral density (BMD) and turnover markers in 26 type 1 (mean age 49 years) and 27 type 2 (mean age 65 years) diabetic patients without known osteoporosis from a community-based sample at baseline and 5 years later. In the 17 type 1 men, BMD fell at the femoral neck (0.804 ± 0.

Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study.

Objective: To determine the incidence of lactic acidosis in community-based patients with type 2 diabetes, with special reference to metformin therapy.

Design: Substudy within a longitudinal observational study, the Fremantle Diabetes Study (FDS).

Participants And Setting: 1279 patients from a postcode-defined population of 120 097 people in Western Australia.

Tesaglitazar.

AstraZeneca plc is developing tesaglitazar, an oral dual peroxisome proliferator-activated receptor alpha/gamma agonist, for the potential improvement of dyslipidemia and glycemic control in type 2 diabetic patients.